Advertisement

ADVERTISEMENT

Jolynn Tumolo

News
Higher Dose Anti-VEGF Therapy May Improve Treatment-Resistant Neovascular AMD
02/22/2022
Jolynn Tumolo
Patients with treatment-resistant age-related macular degeneration benefited from higher doses of intravitreal bevacizumab, ranibizumab, and aflibercept, showing continuous improvements in central retinal thickness across several months,...
Patients with treatment-resistant age-related macular degeneration benefited from higher doses of intravitreal bevacizumab, ranibizumab, and aflibercept, showing continuous improvements in central retinal thickness across several months,...
Patients with...
02/22/2022
First Report Managed Care
News
During Pandemic’s First Year, Physician Visits for Mental Health, Substance Use Increased
02/18/2022
Jolynn Tumolo
Outpatient mental health and substance use visits among physicians increased substantially during the first year of the COVID-19 pandemic, according to a population-level cohort study of physicians in Ontario, Canada. Researchers published...
Outpatient mental health and substance use visits among physicians increased substantially during the first year of the COVID-19 pandemic, according to a population-level cohort study of physicians in Ontario, Canada. Researchers published...
Outpatient mental health and...
02/18/2022
Psych Congress Network
News
Dementia Linked With Better End-of-Life Care for Patients With Respiratory Disease
02/17/2022
Jolynn Tumolo
Family members perceived better end-of-life care for patients with dementia who died of noncancerous respiratory disease compared with patients who did not have dementia.
Family members perceived better end-of-life care for patients with dementia who died of noncancerous respiratory disease compared with patients who did not have dementia.
Family members perceived better...
02/17/2022
Annals of Long-Term Care
News
Cold Tablets Recalled
02/17/2022
Jolynn Tumolo
Millions of cold tablets sold in bulk containers are under a Class II recall.
Millions of cold tablets sold in bulk containers are under a Class II recall.
Millions of cold tablets sold in...
02/17/2022
Pharmacy Learning Network
News
Acetaminophen Products Recalled
02/17/2022
Jolynn Tumolo
Various acetaminophen products are being voluntarily recalled by Ultra-Tab Laboratories Inc.
Various acetaminophen products are being voluntarily recalled by Ultra-Tab Laboratories Inc.
Various acetaminophen products...
02/17/2022
Pharmacy Learning Network
News
Antacid Tablets Recalled
02/17/2022
Jolynn Tumolo
A Class II recall has been issued for numerous antacid products.
A Class II recall has been issued for numerous antacid products.
A Class II recall has been...
02/17/2022
Pharmacy Learning Network
News
Study Ranks Disease-Modifying Therapies for Relapsing-Remitting MS
02/16/2022
Jolynn Tumolo
Authors of a systematic review ranked therapies for multiple sclerosis across multiple outcomes including effectiveness, patient compliance, reduced disability progression risk, and improved magnetic resonance imaging outcomes. 
Authors of a systematic review ranked therapies for multiple sclerosis across multiple outcomes including effectiveness, patient compliance, reduced disability progression risk, and improved magnetic resonance imaging outcomes. 
Authors of a systematic review...
02/16/2022
First Report Managed Care
News
Cognitive Training Impact in Patients With Parkinson Disease
02/15/2022
Jolynn Tumolo
Resting-state brain networks were not enhanced by cognitive training in patients with Parkinson disease, according to authors of a recent study.
Resting-state brain networks were not enhanced by cognitive training in patients with Parkinson disease, according to authors of a recent study.
Resting-state brain networks...
02/15/2022
Annals of Long-Term Care
News
Once-daily Therapy Improves Motor Function in Types 2 and 3 Spinal Muscular Atrophy
02/14/2022
Jolynn Tumolo
Once-daily treatment with risdiplam was more efficacious than placebo in improving motor function in patients with types 2 and 3 spinal muscular atrophy, and research is ongoing to determine the drug's long-term efficacy and safety.
Once-daily treatment with risdiplam was more efficacious than placebo in improving motor function in patients with types 2 and 3 spinal muscular atrophy, and research is ongoing to determine the drug's long-term efficacy and safety.
Once-daily treatment with...
02/14/2022
First Report Managed Care
News
Ketamine Increases Abstinence Days in Patients With Severe Alcohol Use Disorder
02/11/2022
Jolynn Tumolo
Three weekly ketamine infusions were associated with more days of alcohol abstinence at a 6-month follow-up in patients with severe alcohol use disorder, according to a double-blind, phase 2 trial published in the American Journal of...
Three weekly ketamine infusions were associated with more days of alcohol abstinence at a 6-month follow-up in patients with severe alcohol use disorder, according to a double-blind, phase 2 trial published in the American Journal of...
Three weekly ketamine infusions...
02/11/2022
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
October 29 ⁠–⁠ November 2
November 1 ⁠–⁠ November 2
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use